Adjuvant immunotherapy after kidney surgery — who it is for, and who does not need it

Adjuvant means added after the main treatment, not instead of it. Once the affected kidney, or the tumour within it, has been removed, the operation has dealt with everything the surgeon could see. Adjuvant immunotherapy is a course of an immune checkpoint inhibitor of the PD-1 class given afterwards, aimed at cancer cells that may have slipped away before surgery and are far too few to show on any scan. It is not treating visible disease, because on a clear post-operative scan there is none left to see. It is given by infusion on a repeating cycle for a fixed period set by the protocol rather than indefinitely, and NCCN guidance supports discussing it where the pathology report points to a high risk of the cancer returning. At CION the infusions and the monitoring around them are delivered in-house by our medical oncology team.

Not everyone who has a kidney removed. The decision is made from the pathology report on the tissue that came out, not from the scan taken before surgery. Your oncologist reads how far the tumour had grown, whether it had spread beyond the kidney or into a vein, whether any lymph node contained cancer, the grade, whether sarcomatoid change was present, and whether a deposit elsewhere was removed at the same time. Where those features together point to a high risk of recurrence, adjuvant treatment is worth discussing. Where they do not, surveillance alone is usually the better answer, because treatment carries real side effects and should not be given without a reason. Your general health, kidney and liver function, thyroid status, any autoimmune condition and any long-term steroid or immunosuppressant use are weighed alongside.

It is a defined course rather than an open-ended one, and that is one of the important differences from treatment for advanced disease. The infusions are given on a repeating cycle for a fixed period written into the protocol, after which they stop by design even when everything has gone well. Your oncologist will tell you the exact number of cycles planned for you before you start, and it is entirely reasonable to ask for that in writing. Treatment usually begins only once you have recovered from surgery and the wound has healed, so there is a gap between the operation and the first infusion. Pauses along the way for side effects are common and do not mean the course has failed; the usual plan is to hold treatment, settle the problem, and then resume.

A checkpoint inhibitor works by removing a restraint on your own immune system, so its side effects come from immune activity in normal organs rather than from a drug attacking healthy tissue the way chemotherapy does. The thyroid, the skin, the bowel, the liver, the lungs and the pituitary and adrenal glands are the usual sites. Most are manageable when picked up early, which is why bloods are checked before every cycle, and why a new rash, persistent loose motions, breathlessness, a dry cough, unusual tiredness or dizziness should be reported the same day rather than saved for the next appointment. Treatment is often held and steroids started while things settle. A few effects, thyroid ones in particular, can be permanent and need lifelong tablets. Side-effect management at CION is handled in-house by the medical oncology team.

Surveillance is a real plan, not a decision to do nothing. It means a schedule of clinic reviews, blood tests and scans at set intervals, arranged so that if the cancer does come back it is found while it is small and still treatable. For many people whose pathology report shows a lower risk of recurrence, that is the recommended option rather than a compromise. The trade-off is honest on both sides. Adjuvant treatment aims to lower the chance of recurrence, but gives side effects to some people who would never have needed it. Surveillance avoids those side effects and accepts that recurrence, if it happens, is treated when it shows up. Ask your oncologist to set out both paths against your own report before you decide.

The drug class is the same, but the situation and the intent are not. Adjuvant treatment is given after surgery has removed all the visible disease, aims to reduce the chance of the cancer returning, and runs for a fixed period. Immunotherapy for advanced kidney cancer is given when disease is present on scans, aims to control and shrink it, is often paired with a second drug class, and carries on while it is working and while you are tolerating it. Because there is nothing to measure in the adjuvant setting, scans are used to confirm that the cancer has not returned rather than to judge whether the drug is shrinking anything. Our page on immunotherapy for advanced kidney cancer covers that other setting in full.